Alzheimer's disease how it works ?

Alzheimer's disease treatments represent worldwide huge challengers and are among the most important nowadays concerns. The goal of the congress is to bring together today's worldwide leaders in the treatment of Alzheimer's disease in order to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments. It will also allow the participants to share their experience on the disease symptoms, and their skills on the dementia treatment. New goals for the Alzheimer's disease treatments are to identify the new biomarkers as well as more sensitive clinical assessment tools in order to predict progression, and assess the effectiveness of new treatments. Safe drugs represent some of the future treatment trials in order to avoid Alzheimer's disease progression. The importance of non-pharmaceutical trials and that anti-amyloid treatment for AD was shown at the 2018 CTAD Congress. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. New examples of trials will be highlighted in the 2019 CTAD Congress. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.

Scientific committee

  • Susan ABUSHAKRA (Chief Medical officer)
  • Paul AISEN (Professor)
  • Kaj BLENNOW (Professor)
  • Merce BOADA (Chief Medical)
  • Maria CARRILLO (Chief Science Officer at Alzheimer's Association)
  • Mony John DE LEON (New York)
  • Steven DEKOSKY (Professor of Neurology)
  • Rachelle DOODY (Global Head of Neurodegeneration)
  • Bruno DUBOIS (Paris)
  • Howard FELDMAN (Vancouver)
  • Nick FOX (London)
  • Giovanni B. FRISONI (Brescia, Geneva)
  • Lutz FROELICH (Mannheim)
  • Serge GAUTHIER (Montreal)
  • Ezio GIACOBINI (Professor at University of Geneva)
  • Michael GRUNDMANN (San Diego)
  • Harald HAMPEL (Neurology Business Group)
  • Takeshi IWATSUBO (Research Associate)
  • Ara KHACHATURIAN (Executive Editor, Alzheimer's & Dementia)
  • Zaven KHACHATURIAN (Alzheimer’s Disease by 2020)
  • Virginia LEE (Philadelphia)

  • Constantine G. LYKETSOS (Baltimore)
  • Jose Luis MOLINUEVO (Barcelona)
  • Jean-Marc ORGOGOZO (Research in clinical Neuroscience)
  • Ronald PETERSEN (Minnesota)
  • Craig W. RITCHIE (Edinburgh)
  • Augustin RUIZ (Senior Clinical Research)
  • Robert RISSMAN (San Diego)
  • Marwan Sabbagh (Las Vegas)
  • Stephen SALLOWAY (Providence)
  • Rachel SCHINDLER (Neurologist, New York)
  • Philip SCHELTENS (Amsterdam)
  • Lon SCHNEIDER (Los Angeles)
  • Eric SIEMERS (Philadelphia)
  • Peter SNYDER (Rhode Island)
  • Reisa SPERLING (Boston)
  • Yaakov STERN (New York)
  • Jacques TOUCHON (Montpellier)
  • John TROJANOWSKI (Philadelphia)
  • Bruno VELLAS (Toulouse)
  • Michael W. WEINER (San Francisco)
  • Bengt WINBLAD (Stockholm)

CTAD Organizing Commitee

Jacques Touchon
Jacques Touchon, MD, PhD University Hospital of Montpellier, France.
Paul Aisen
Paul Aisen, MD Alzheimer's Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego
Bruno Vellas
Bruno Vellas, MD, PhD University Hospital of Toulouse, France.
Michael Weiner
Mike Weiner, MD University of California San Francisco (UCSF), USA